Previous 10 | Next 10 |
Novocure (NVCR) has received the CE Mark for the NovoTTF-100L system, for the commercialization of the device as a first-line treatment in combination with Eli Lilly's Alimta (pemetrexed) and platinum-based chemotherapy for malignant pleural mesothelioma ((MPM)), in the Europea...
Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investo...
Provides flexible capital structure prior to anticipated period of significant innovation and growth Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 millio...
Initial conversion price represents a premium of approximately 50% Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the closing of its previously announced offering of $575 million ...
Novocure (NVCR) has priced $500M of its 0% convertible senior unsecured notes due November 1, 2025 through a private placement.Initial purchasers granted an option to purchase additional $75M of notes.Closing date is November 5. Special interest on the notes, if any, will be payabl...
Initial conversion price represents a premium of approximately 50% Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% C...
Novocure (NVCR) to offer $500M of convertible senior notes due 2025, via a private placement. Initial purchasers have an option to purchase up to an additional $75M notes.Net proceeds will be used to further advance the company's clinical and product development programs and to invest in asso...
Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”). The notes will ...
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q3 2020 Earnings Call Transcript
Novocure Ltd (NVCR) Q3 2020 Earnings Conference Call October 29, 2020, 08:00 ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger - President, CEO & Director Ashley Cordova - CFO & VP, IR Ely Benaim - Chief Medical Officer Uri Wei...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...